- Home
- HPAI vs NBTX Comparison
HPAI vs NBTX Comparison
Compare HPAI & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPAI
- NBTX
- Stock Information
- Founded
- HPAI 2023
- NBTX 2003
- Country
- HPAI Singapore
- NBTX France
- Employees
- HPAI N/A
- NBTX N/A
- Industry
- HPAI
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- HPAI
- NBTX Health Care
- Exchange
- HPAI NYSE
- NBTX Nasdaq
- Market Cap
- HPAI 221.3M
- NBTX 178.7M
- IPO Year
- HPAI N/A
- NBTX 2020
- Fundamental
- Price
- HPAI $5.00
- NBTX $3.29
- Analyst Decision
- HPAI
- NBTX Strong Buy
- Analyst Count
- HPAI 0
- NBTX 1
- Target Price
- HPAI N/A
- NBTX $8.00
- AVG Volume (30 Days)
- HPAI 39.2K
- NBTX 11.4K
- Earning Date
- HPAI 03-31-2025
- NBTX 04-02-2025
- Dividend Yield
- HPAI N/A
- NBTX N/A
- EPS Growth
- HPAI N/A
- NBTX N/A
- EPS
- HPAI 0.06
- NBTX N/A
- Revenue
- HPAI $31,475,664.00
- NBTX N/A
- Revenue This Year
- HPAI N/A
- NBTX N/A
- Revenue Next Year
- HPAI N/A
- NBTX $277.81
- P/E Ratio
- HPAI $88.84
- NBTX N/A
- Revenue Growth
- HPAI 47.72
- NBTX N/A
- 52 Week Low
- HPAI $3.07
- NBTX $2.76
- 52 Week High
- HPAI $14.74
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- HPAI N/A
- NBTX 46.34
- Support Level
- HPAI N/A
- NBTX $3.28
- Resistance Level
- HPAI N/A
- NBTX $3.53
- Average True Range (ATR)
- HPAI 0.00
- NBTX 0.18
- MACD
- HPAI 0.00
- NBTX 0.00
- Stochastic Oscillator
- HPAI 0.00
- NBTX 46.48
About HPAI HELPORT AI LTD
Helport AI Ltd is a AI technology company based in Singapore dedicated to serving enterprises' customer contact centers with intelligent products, solutions, and a digital platform. Its software, Helport AI Assist (AI Assist), provides tailored AI-powered guidance and oversight for contact center interactions and customer experience, with functions including Agent Assistant, Quality Assurance (QA) Assistant, Supervisor Assistant, and Knowledge Base Assistant.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.